The anti-tumor immune response can be suppressed by TIGIT, which is an inhibitory molecule on CD8+ effector memory T cells, and inhibitors of TIGIT combined with anti-PD1 are promising to reduce PD1 inhibitor resistance (Chiu et al., 2020; Ostroumov et al., 2021). This evidence concerns the gene CD8A and neoplasm.